CRSP - CRISPR Therapeutics AG
NEXT EARNINGS:
May 11, 2026
EPS Est: $-1.24
|
Rev Est: $5.1M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$65.00
DETAILS
HIGH:
$82.00
LOW:
$33.00
MEDIAN:
$74.50
CONSENSUS:
$65.00
UPSIDE:
14.50%
Market Cap:
5.45B
Volume:
1,687,791
Avg Volume:
1,732,120
52 Week Range:
30.04-78.48
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.75
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
CH
Employees:
393
IPO Date:
2016-10-19
EPS (TTM):
-6.47
P/E Ratio:
-8.11
Revenue (TTM):
3.51M
Total Assets:
2.27B
Total Debt:
394.91M
Cash & Equiv:
355.19M
Rev Growth (5Y):
37.3%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-26.9%
Debt/Equity:
0.21
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-12 | $-1.37 | $-1.15 | -19.1% | $864000 | $4.7M | -81.7% |
| 2025-11-10 | $-1.17 | $-1.26 | +7.1% | $889000 | $9.1M | -90.3% |
| 2025-08-04 | $-1.29 | $-1.47 | +12.2% | $892000 | $9.4M | -90.5% |
| 2025-05-06 | $-1.58 | $-1.27 | -24.4% | $865000 | $6.0M | -85.5% |
| 2025-02-11 | $-0.44 | $-1.15 | +61.7% | $35.0M | $8.1M | +334.5% |
| 2024-11-05 | $-1.01 | $-1.33 | +24.1% | $602000 | $7.7M | -92.2% |
| 2024-08-05 | $-1.49 | $-1.37 | -8.8% | $517000 | $16.6M | -96.9% |
| 2024-05-08 | $-1.43 | $-1.63 | +12.3% | $504000 | $3.5M | -85.8% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.51M | 35.00M | 370.00M | 436,000 | 913.08M | 719,000 | 289.59M | 3.12M | 41.00M | 5.16M | 247,000 | 0 |
| Net Income | (581.60M) | (366.25M) | (153.61M) | (650.17M) | 377.66M | (348.87M) | 66.86M | (164.98M) | (68.36M) | (23.20M) | (25.83M) | (6.80M) |
| EPS | -6.47 | -4.34 | -1.94 | -8.36 | 4.97 | -5.29 | 1.23 | -3.44 | -1.71 | -1.89 | -0.88 | -0.23 |
| Total Assets | 2.27B | 2.24B | 2.23B | 2.24B | 2.75B | 1.83B | 1.07B | 489.02M | 271.35M | 344.96M | 159.42M | 1.53M |
| Total Debt | 394.91M | 223.69M | 238.63M | 244.02M | 225.03M | 61.43M | 52.54M | 0 | 0 | 0 | 38.34M | 0 |
| Cash & Equivalents | 355.19M | 298.26M | 389.48M | 211.88M | 923.03M | 1.17B | 943.77M | 456.65M | 239.76M | 315.52M | 155.96M | 945,000 |
| Operating Cash Flow | (345.01M) | (142.77M) | (260.38M) | (495.74M) | 538.97M | (238.37M) | 56.68M | (96.24M) | (70.10M) | (55.31M) | 59.43M | (4.79M) |
| Free Cash Flow | (345.93M) | (144.68M) | (269.85M) | (532.93M) | 457.27M | (256.72M) | 49.99M | (99.01M) | (77.91M) | (58.33M) | 58.27M | (4.79M) |
| FCF per Share | -3.85 | -1.71 | -3.41 | -6.85 | 6.02 | -3.89 | 0.92 | -2.06 | -1.95 | -4.76 | 1.99 | -0.16 |
| Book Value | 1.92B | 1.93B | 1.88B | 1.88B | 2.40B | 1.66B | 939.42M | 392.19M | 187.83M | 232.85M | (29.10M) | (7.12M) |
| Cash & ST Investments | 1.98B | 1.90B | 1.69B | 1.82B | 2.38B | 1.69B | 943.77M | 456.65M | 239.76M | 315.52M | 155.96M | 945,000 |
| ROC Equity | -0.30 | -0.19 | -0.08 | -0.35 | 0.16 | -0.21 | 0.07 | -0.42 | -0.36 | -0.10 | N/A | N/A |